| Document |
Document Title |
|
WO/2011/064552 |
A construct suitable for delivery of a biologically active compound into cells, comprising: (d) a positively charged peptide; (e) a targeting-delivery peptide; and (f) the biologically active compound; wherein the positively charged pept...
|
|
WO/2011/065791 |
The present invention provides a composition comprising Astragali Radix extract as an active ingredient. The composition can increase body energy consumption and muscle metabolism. The present invention also relates to pharmaceutical and...
|
|
WO/2011/062253 |
Disclosed is a prophylactic and/or therapeutic agent for diseases associated with autoimmunity, immune deficiency diseases or neurodegenerative diseases, said prophylactic and/or therapeutic agent containing a novel fused pyrimidine deri...
|
|
WO/2011/060488 |
The invention relates to a recombinant microorganism comprising a transgene encoding angiogenin and optionally follistatin, a food product, beverage product or animal feed produced from or comprising said microorganism and uses thereof.
|
|
WO/2011/059021 |
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...
|
|
WO/2011/057350 |
An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
|
|
WO/2011/058766 |
The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or –SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have block...
|
|
WO/2011/055944 |
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
|
|
WO/2011/056549 |
Dietary supplement compositions include an adaptogenic agent, an anti- inflammation agent, and an anti-oxidant. Methods for using dietary supplement compositions include (i) inhibiting, decreasing, and/or preventing delayed onset of musc...
|
|
WO/2011/054659 |
The present invention relates to methods for restoring the function of a mutated dysferlin comprising the step of preventing splicing of one or more exons which encode amino acid sequences that cause said dysferlin dysfunction. Particula...
|
|
WO/2011/055944 |
The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.
|
|
WO/2011/050808 |
The invention relates to carbamylated erythropoietin for use in the treatment of Friedrich's ataxia.
|
|
WO/2011/049053 |
It was discovered that myeloid cells, which occurs in the lamina propria of healthy animals and are highly positive to Gr-1, positive to CD11b and positive to CD11c, can induce T cell apoptosis and, in its turn, inhibit T cell activation...
|
|
WO/2011/048350 |
A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the pati...
|
|
WO/2011/050262 |
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
|
|
WO/2011/047093 |
The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair dif...
|
|
WO/2011/047093 |
The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair dif...
|
|
WO/2011/041937 |
The use of hydroxytyrosol or an olive juice extract containing hydroxytyrosol for improving muscle differentiation and thus improving or maintaining the body's adaptation to exercise is disclosed. The pharmaceutical and nutraceutical com...
|
|
WO/2011/038471 |
The technical subject matter of the present invention relates to a pharmaceutical composition that contains, as the active principle, substances obtained by extraction and purification of essential oils from a plant of the Alpinia genus....
|
|
WO/2011/040823 |
The present invention relates to novel synthetic myostatin antagonists, comprising a synthetic mature myostatin peptide, wherein the peptide comprises at least two cysteine residues at positions 281 and 282 which are forced to bond and f...
|
|
WO/2011/034912 |
Disclosed are methods of treating spasticity by administering to a patient in need of such treatment a compound having formula (I).
|
|
WO/2011/034078 |
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...
|
|
WO/2011/034532 |
Disclosed are compositions, formulations and methods relating to one or more stilbene-based compounds for use in humans. In particular, compositions and formulations comprising an effective amount of the stilbene-based insulinogenic comp...
|
|
WO/2011/033884 |
A pharmaceutical material or a food material which contains a caroteine oxidation derivative derived from a land animal, a land plant or a microorganism as an active ingredient, is suitable for use in a food, a beverage or a drug, and ca...
|
|
WO/2011/034920 |
Disclosed are methods of treating a seizure disorder by administering to a patient in need of such treatment a compound having the following formula (I).
|
|
WO/2011/030981 |
A method for preparing [18F]fallypride is disclosed, which comprises a first step for trapping a fluorine-18 to a polymer ion exchange cartridge; a second step for extraction of fluorine-18 by inputting low base concentrations: 5.0~25μL...
|
|
WO/2011/031901 |
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist ...
|
|
WO/2011/030116 |
This invention pertains to the use of steroid compounds including spirosteroid analogues in treating, preventing or ameliorating the symptoms of inflammatory conditions. The steroid compounds are useful for treating a range of inflammato...
|
|
WO/2011/024077 |
Methods for stabilizing unstable proteins or for restoring functionality to non-functional or poorly functioning (semi-functional) proteins using exon skipping technology are provided. The methods involve the administration of antisense ...
|
|
WO/2011/024822 |
Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeut...
|
|
WO/2011/025368 |
Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vit...
|
|
WO/2011/021678 |
Disclosed are: a fused heterocyclic compound having excellent medical activities including a p38 MAPK-inhibiting activity and a TNF-α production-inhibiting activity; a medicinal agent comprising the compound; and others. Specifically di...
|
|
WO/2011/022491 |
This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine preci...
|
|
WO/2011/020874 |
The invention relates to methods for the treatment of Duchenne muscular dystrophy and to methods for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy. More particularly, the present invention relates to a ...
|
|
WO/2011/018588 |
The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3- or hydroxyl group, R3 is an alkyl, c...
|
|
WO/2011/019348 |
Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.
|
|
WO/2011/018587 |
The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are OSO3- or hydroxyl groups, R2 is an O-alkyl group or a monosaccharide having Formula (II), R3 is a disaccha...
|
|
WO/2011/016814 |
Disclosed are compounds such as 5α-androstane-3, 6, 17- trione, formulations comprising said compounds, and methods of use thereof to stimulate endogenous testosterone production and improve athletic performance and libido.
|
|
WO/2011/016459 |
Disclosed is a compound which has serotonin 5-HT2C receptor activating activity. Specifically disclosed is a compound represented by formula (I) or a salt thereof. (In the formula, the symbols are as defined in the description.)
|
|
WO/2011/013785 |
Disclosed are a compound represented by general formula [I], a pharmaceutically acceptable salt thereof or a solvate of the same, and medicinal use thereof for treating rejection in organ transplantation, graft-versus-host reaction after...
|
|
WO/2011/014084 |
The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloa...
|
|
WO/2011/013646 |
Disclosed is a pharmaceutical product for prevention and treatment of sporadic amyotrophic lateral sclerosis, which contains, as an active ingredient, a substance that is selected from the group consisting of (a) leucomycins and oleandom...
|
|
WO/2011/013470 |
Disclosed is an autoantibody production inhibitor which can inhibit an autoantibody specifically and can prevent or treat autoantibody autoimmune diseases effectively. The autoantibody production inhibitor is characterized by comprising,...
|
|
WO/2011/013699 |
A foreign substance introduction method, which comprises the steps of: preparing a foreign substance introduction construct comprising a carrier peptide fragment and a foreign substance of interest bound to the N-terminal side and/or the...
|
|
WO/2011/010682 |
Disclosed is a sterol derivative, which has an effect of promoting the proliferation of nerve stem cells, or a pharmaceutically acceptable salt of the same. Specifically disclosed is a sterol derivative represented by general formula (I)...
|
|
WO/2011/011252 |
Nutritional compositions and methods of using the nutritional compositions with exercise to attenuate the loss of functional status are provided. In a general embodiment, the present disclosure provides a nutritional composition includin...
|
|
WO/2011/009075 |
The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds an...
|
|
WO/2011/007794 |
The present invention is directed to improve the usefulness of zeolite and sericite in various medical fields. To achieve this purpose, a composition for medical or medical assisting uses, which contains zeolite and sericite, is provided...
|
|
WO/2011/007866 |
Disclosed are an agent which is capable of correcting splicing disorders of myotonic dystrophy, and a use of the agent. Specifically disclosed is an agent for treatment of myotonic dystrophy, which contains a compound the medicinal effec...
|
|
WO/2011/003129 |
The present invention relates to a method for slowing the development of mammalian organ, tissue and cellular damage and death by using a persistent sodium current blocker (or a pharmaceutically acceptable salt or derivative thereof). Th...
|
